A session at the US Centers for Medicare and Medicaid Services' recent New Technology Add-on Payment Town Hall offered a window into how regulatory decisions made during development and in discussions with FDA can play an important role in payment years down the road.
In the case of Progenics Pharmaceuticals Inc., the decision related to a primary endpoint choice in order to pursue...







